Could a common cholesterol drug ease Parkinson's symptoms?

NCT ID NCT05931484

Not yet recruiting Disease control Sponsor: Forest Hills Lab Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether FHL-301 (gemfibrozil, a drug usually used for cholesterol) can help control motor symptoms in people with early-stage Parkinson's disease. Thirty-two adults aged 40 to 75 will receive either the drug or a placebo for up to 48 weeks. The main goal is to see if it improves movement scores on a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemfibrozil (a cholesterol-lowering drug, repurposed as FHL-301)
What this could lead to: If successful, this could point toward a new way to slow or manage motor symptoms in early Parkinson's disease.
What could go wrong: This is a small, early-phase trial with only 32 people. The drug is being repurposed, so it may not work for Parkinson's, and side effects like stomach upset are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.